Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
- GARAMYCIN®, INJEKTIONSVÄTSKA OCH INFUSIONSKONCENTRAT 80 MG/ML, SCHERING-PLOUGH AB
- SYNAGIS™, INJEKTIONSSUBSTANS I+II 100 MG, ABBOTT SCANDINAVIA AB
- BERIGLOBIN®, INJEKTIONSVÄTSKA, LÖSNING 160 MG/ML, AVENTIS BEHRING AB
- CLINDAMYCIN RATIOPHARM®, INJEKTIONS-/INFUSIONSVÄTSKA, LÖSNING 150 MG/ML, RATIOPHARM AB
Infectious Diseases Drug Data - A-Z (Svenska)
Drug Description
1 enterotablett innehåller: Erythromycin. 250 mg, constit. et color (titandioxid E171) q. s.Presentation
Enterotabletter 250 mgIndications
Pneumoni orsakad av Mycoplasma pneumoniae, Chlamydia psittaci (ornitos) eller Chlamydia pneumoniae (TWAR). Kikhosta. Difteri. Urogenitala infektioner orsakade av Chlamydia trachomatis.Vid följande indikationer bör ABBOTICIN förbehållas patienter med penicillinöverkänslighet eller där penicillin är olämpligt av andra skäl: Faryngotonsillit. Akut otitis media. Samhällsförvärvad pneumoni. Hud- och mjukdelsinfektioner.
Adult Dosage
Normaldos för vuxna samt barn över 35 kg: 500 mg (2 tabletter) 2 gånger per dygn. Alternativt ges 250 mg 4 gånger per dygn. Vid svårare infektioner ges 500 mg 3—4 gånger per dygn. Tabletterna får ej delas eller tuggas utan skall sväljas hela.Behandlingskontroll
Speciellt vid långtidsbehandling eller upprepad terapi kan överväxt av icke känsliga bakterier eller svampar inträffa. Erytromycin skall då utsättas och lämplig terapi inledas.
Contra Indications
Känd överkänslighet för makrolider. Samtidig medicinering med terfenadin eller cisaprid.Special Precautions
Eftersom erytromycin huvudsakligen utsöndras via levern skall försiktighet iakttas vid administrering till patienter med nedsatt leverfunktion.Det finns rapporter om att erytromycin kan förvärra symptomen hos Myasthenia gravis-patienter.
Interactions
Kombination med terfenadin bör undvikas, D.Följande kombinationer med ABBOTICIN kan kräva dosanpassning, C: alfentanil, alprazolam, bromokriptin, ciklosporin, cimetidin, dihydroergotamin, disopyramid, ergotamin, karbamazepin, klozapin, metylprednisolon, midazolam, takrolimus, teofyllin, triazolam, warfarin och zopiklon.
Se speciellt avsnitt märkt , J01F A01 Erytromycin.
Erytromycin interagerar med metabolismen av fenytoin, vilket kan resultera i ökade plasmakoncentrationer av fenytoin. Förhöjda cisapridnivåer har rapporterats hos patienter som fått erytromycin och cisaprid samtidigt. Detta kan resultera i förlängt QT-intervall och hjärtarytmier inkluderande ventrikulär takykardi, ventrikelflimmer och torsade de pointes.
Adverse Reactions
Gastrointestinala besvär uppträder i 10—15% av fallen. De är dosberoende och kan upphöra under behandlingen.- Vanliga (>1/100) - GI: Magknip, illamående, diarré. Hud: Utslag.
- Mindre vanliga (1/100 - 1/1000) - Hud: Urtikaria.
- Sällsynta (< 1/1000) - Allmänna: Anafylaxi. Cirk.: Arytmi. GI: Pseudomembranös kolit. Lever: Förhöjda leverenzymvärden, bilirubinstegring, intrahepatisk gallstas. Öron: Reversibel hörselförlust.
För att minska eventuella gastrointestinala besvär bör ABBOTICIN intagas omedelbart före måltid.
Erytema multiforme, Stevens-Johnsons syndrom och toxisk epidermal nekrolys har rapporterats i enstaka fall.
Manufacturer
Abbott Scandinavia ABAdvert for Healthcare Professionals Only
Related News
IlLLUMINATE trial of Incivek is published in NEJM Infectious Diseases Page
The New England Journal of Medicine (NEJM) published data from a Phase III study of Incivek(telaprevir) tablets in people with genotype 1 chronic Hepatitis C who were new to treatment. In ILLUMINATE, Incivek was given for the first 12 weeks in combination with pegylated-interferon and ribavirin. Nearly two-thirds of patients responded early to Incivek combination treatment (measured by having undetectable hepatitis C virus at weeks 4 and 12 of treatment) and were randomly assigned to receive an additional 12 weeks or 36 weeks of treatment with pegylated-interferon and ribavirin alone. Similarly high rates of sustained viral response (SVR, or viral cure) were achieved by people in both treatment groups. Rash and anemia were the most common side effects reported with Incivek in this study and each led to treatment discontinuation of all medicines in about 1 percent of people during the Incivek treatment phase. Data from ILLUMINATE are published in the September 15, 2011 issue of NEJM.
Incivek treatment still effective when course is half as long in treatment of Hepatitis C genotype 1 Infectious Diseases Page
A Phase III study (ADVANCE) of Incivek (telaprevir) tablets in patients with genotype 1 chronic Hepatitis C published in The New England Journal of Medicine (NEJM) reveals that a 24-week treatment course that adds Incivek to peginterferon alfa and ribavirin is just as effective as a 48-week regimen for many patients. Shortening the duration of treatment reduces a patient's exposure to side effects including rash and anemia.see Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection September 15, 2011Sherman K.E., Flamm S.L., Afdhal N.H., et al.N Engl J Med 2011; 365:1014 - 1024.
Vibativ is EU approved for nosocomial pneumonia caused by MNSA Infectious Diseases Page
Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Its labelling will include its use in the treatment of adults with nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. In the US and Canada, the drug was approved in 2009 for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of certain Gram-positive microorganisms, including Staphylococcus aureus ,including methicillin-susceptible and-resistant isolates but is not approved in these territories for the pneumonia indication. Vibativ is not yet available in Europe for use with skin such infections as are approved in the USA.
More News
